November 29, 2017Open Access

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Key Points

Key points are not available for this paper at this time.

Abstract

In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Eli L. Diamond

Vivek Subbiah

A. Craig Lockhart

Journals

JAMA Oncology

Actions

Institutions

Cornell University

Massachusetts General Hospital

Memorial Sloan Kettering Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study